The alterations induced in gut microbiota by tacrolimus may affect immune function and organ transplantation. Mice were treated with high-dose tacrolimus for 14 days.
The fecal microbiota were analyzed by pyrosequencing the 16S rRNA genes, and the effect on metabolism was predicted using the sequence data. The subgroups of T cells in the serum, gut-associated lymphoid tissue, and draining lymph nodes were deter- Tacrolimus (also known as FK506), a calcineurin inhibitor, is among the most widely used immunosuppressive agents and is used in >93% of transplant recipients. 3, 4 Conventionally, tacrolimus exerts its immunosuppressive functions by inhibiting calcineurin phosphatase and calcium-dependent events by binding to FK506 binding protein, 5 which prevents the transcription and secretion of interleukin (IL)-2 and the inhibition of T lymphocyte activation. 6 According to many animal and human studies, the gut microbiota is altered after organ transplantation, [7] [8] [9] [10] [11] indicating a close relationship and cross-talk among organ transplantation, the gut microbiota, and the immune system. The gut microbiota contains trillions of microbes that participate in numerous bidirectional interactions with the host and influence immunity via bacterial components and metabolites. 12, 13 Specific metabolites in the gut microbiome play a potential role in immune regulation, such as influencing regulatory T cell (Treg) homeostasis by enhancing the specific expression of transcription factor FoxP3. 14, 15 Fecal microbiota transplantation (FMT), which involves the infusion of a fecal suspension from a donor into the gastrointestinal tract of a recipient, has been reported to alter the gut microbiota community, microbiota metabolism, and immune system. 16 Recently, tacrolimus, at a dosage of 5 mg/kg body weight, was reported to change the gut microbiota in mice fecal samples, although with inconsistent results. 17 However, the relationship between the tacrolimus-modified microbiota and immune function and organ transplant survival is unknown.
In this study, we found that high-dose tacrolimus treatment altered the gut microbiota and bacterial metagenomic function. Treatment via the administration of fecal microbiota in tandem with low-dose tacrolimus in the recipients promoted the development of Tregs in the colonic mucosa (CM), draining lymph nodes, and peripheral blood and resulted in an increased survival rate for skin transplantation (SKT).
Regulation of the gut microbiota may be a new approach for the treatment of graft rejection.
| MATERIALS AND METHODS

| Animal strains and care
C57BL/6 and BALB/c mice (6 to 8 weeks old) were purchased from Vital River Laboratory Animal Technology (Beijing, China). The animals F I G U R E 1 Study design, group designations, and sample sizes. (A) In the tacrolimus function study, the animals were divided into 2 groupsthe Tacro group, which was treated with 10 mg/kg tacrolimus, and the Con group, which was treated with 0.5 mL/d sterile water. The animals were killed on day 14 of treatment, and the gut microbiota community was tested by use of 16S rRNA sequencing. Metagenomics was used for the function prediction, the Treg/Teff cell subsets were assessed by flow cytometry, and the serum cytokines were analyzed by CBA (n = 8 animals/group). (B) Fecal microbiota transplantation (FMT) model. The Tacro group and the Con group received the treatment described in A, and the FMT group was treated with 12.5 mg/d FMT from the high-dose tacrolimus-treated mice for 14 days, followed by the same process shown in A. (C) Skin transplantation study. C-1. Animals were divided into the following 4 groups after receiving a skin transplant from a BABL/c donor: (i) TxSaline group, which was treated with sterile water; (ii) TxTacro group, which was treated with low-dose tacrolimus (0.1 mg/kg); (iii) TxFMT group, which was treated with 12.5 mg/d FMT from the high-dose tacrolimus-treated donor each day; and (iv) TxT+F group, which was treated with a combination of low-dose tacrolimus and FMT. C-2. Timeline of the skin transplantation study design were maintained in a specific pathogen-free facility at the Medical Research Center of Chaoyang Hospital (Beijing, China).
| Experimental design
Three experimental models were designed in our study ( Figure 1 ).
In the tacrolimus functional study ( Figure 1A ), C57BL/6 mice were divided into the control group (Con group, 0.5 mL/d of sterile water, n = 8) and the tacrolimus group (Tacro group, 10 mg/kg per day; dissolved in 0.5 mL sterile water and administered via a daily oral gavage, n = 8) (Advagraf; Astellas Pharma Inc, Tokyo, Japan).
In 
| Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were freshly isolated from blood with the use of Ficoll (Ficoll-Paque PLUS; GE Healthcare, Marlborough, MA) at 600 g for 20 minutes. Draining lymph node cells were isolated by grinding through a 40-μm sterile nylon filter in RPMI.
CM lymphocytes were isolated according to a previously described method. 18 The cells were stimulated with Leukocyte Activation
Cocktail (BD PharMingen, San Jose, CA) via incubation in 5% CO 2 for 4 hours at 37°C and then stained for surface and intercellular markers. (Table S1 ).
| Cytometric bead assay
The peripheral blood serum was separated via centrifugation at 1000 g for 10 minutes, and the levels of IL-4, IL-5, TNF-α, and IFNγ were determine by using Cytometric Bead Array kits as recommended by the manufacturer (BD Bioscience).
| Immunohistochemistry
The skin specimens were fixed with 4% paraformaldehyde, dehydrated, and embedded in paraffin. The specimens were cut into 4-μm sections.
After the inactivation of endogenous peroxidase and blocking of nonspecific antibody binding, the specimens were treated with antibodies specific to CD68 (1:250 dilution; Abcam, Cambridge, MA) at 4°C overnight.
Subsequently, the sections were incubated with horseradish peroxidase detection reagent (Immunohistochemistry Application Solutions Kit; Cell
Signal Technology, Danvers, MA) for 30 minutes at room temperature.
| Colony-forming assay
The fresh fecal sample (0. 
| 16S rRNA Illumina (Illumina Inc., San Diego, CA) sequencing
The fresh fecal samples were collected aseptically on the morning of the corresponding date. The bacterial genomic DNA was extracted from all samples, and pyrosequencing was performed by Ribobio Inc.
(Guangzhou, China).
| Bioinformatic analyses
The bioinformatic analyses were performed by using the methods described by Rabbi et al 19 and DeSantis et al. 20 The within-community diversity (α-diversity) and variation in community composition (β-diversity) were calculated by using Quantitative Insights Into Microbial Ecology (QIIME). 21 Principal component analysis (PCA) was applied to the resulting distance matrices to generate a plot using statistical analysis of metagenomic profiles software (STAMP). 22 Analysis of similarities (ANOSIM) was performed using PRIMER-E 7.0 to test the significant separation among the groups. The linear discriminant analysis (LDA) and LDA effect size (LEfSe) methods were used to compare and visualize the significant differences in the taxa among the groups.
| Metagenomic functional prediction
The phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) analysis was performed as described by
Langille et al 23 to predict the functional capacity of the gut microbiota.
The PICRUSt data were analyzed by using STAMP.
| Statistical analysis
Continuous variables are presented as the mean ± SEM. Meier analysis was performed, and the difference was tested by performing the log rank test. All analyses were performed by using SPSS
(SPSS, Chicago, IL)
. A value of P < .05 was considered significant.
| RESULTS
| Tacrolimus alters the β-diversity of the gut microbiota
The serum tacrolimus concentration in the Tacro group ranged from 2 to 5 ng/mL ( Figure S1 ), which was the highest tolerated dose that most closely resembled the serum concentration in humans (8-12 ng/mL). No significant differences were observed in the CFUs and α-diversity between the Tacro group and the Con group on both day 0 and day 14 (Table 1, Figure S2 ).
PCA was performed by using the OTU data ( Figure 2 ). The community structure in the Tacro group on day 14 was clearly distinct from that in the Tacro group on day 0 and the Con group on days 0 and 14, and the first 2 principal components represented 48.3% and 31.3%
of the total variations. The ANOSIM test confirmed that a significant separation occurred between the Tacro group and the other 3 groups (P < .05, weighted Spearman rank).
| High-dose tacrolimus alters the composition and bacterial taxa of the gut microbiota
According to the gut microbiota community analysis, 14 phyla, 23 classes, 41 orders, 67 families, and 112 genera were present in each sample of the Con group and the Tacro group on days 0 and 14 ( Figures S3 and S4) . Compared with the Con group, the relative abundance of Allobaculum, Bacteroides (P < .01), and Lactobacillus (P < .05) significantly increased, while the abundance of Clostridium (P < .01), Ruminococcus, Rikenella, Ruminococcaceae, and Oscillospira (P < .05) significantly decreased in the Tacro group on day 14 ( Figure 3A , B). Among the 3 most highly increased bacteria genera, Allobaculum exhibited the greatest significant increase in the Tacro group. A cladogram representation of the significant differences in the taxa between the Con group and the Tacro group was generated by using LEfSe ( Figure 3C ). The colored nodes from the inner to the outer circles represent the abundant taxa from the phylum to the genus level, and the green labels represent the taxa enriched in the Tacro group, while the red labels represent the taxa enriched in the Con group. Continuous independent variables were used in the LDA model to predict the dependent variable (LDA > 2, P < .05) ( Figure 3D was the most significantly enriched in the Con group. In total, 9 significantly different families were observed with the use of LEfSe.
Overall, tacrolimus influenced the taxa of the gut microbiota.
T A B L E 1 CFUs and α-diversity of control and tacrolimus groups F I G U R E 2 Overall view of the high-dose tacrolimus-influenced gut microbiota community. PCA showed similar community structures between the control and tacrolimus groups at the beginning and end of the study, and the first 2 principal components represented 48.3% and 31.3% of the total variations. The ANOSIM test confirmed that a significant separation occurred between the Tacro group on day 14 and the Con group on days 0 and 14 and the Tacro group on day 0 (P < .05, weighted Spearman rank)
The influence of tacrolimus at moderate (1 mg/kg) and low (0.1 mg/kg) dosages on the gut microbiota was also analyzed. In the gut microbiota community, only Allobaculum changed after the 1 mg/kg-dose tacrolimus treatment (P < .05), while none of the gut microbiota significantly changed after low-dose tacrolimus treatment (0.1 mg/kg) ( Figure S5 ).
| High-dose tacrolimus is predicted to alter microbiota function
To predict the microbiota functions altered by tacrolimus, a PICRUSt analysis was performed based on the 16S rRNA OTU Figure 4A ).
PCA was also performed based on the PICRUSt data ( Figure 4B ).
The community microbiota functions in the Con group and the Tacro group were clearly distinct based on the first 2 principal components, which represented 64.8% and 22.4% of the total variations.
| High-dose tacrolimus-altered gut microbiome influences immune function in vivo
The gut microbiota were analyzed in all 3 groups of the FMT model on both day 0 and day 14 ( Figures 5 and S6 ). At 14 days after the FMT, the only significant different was the genus Bacteroides in the FMT recipient group, which was significantly lower than that in the Tacro group but remained higher than that in the Con group (P < .05).
The PBMCs were characterized as CD4 + T cells, CD8 + T cells, Relative abundances of 8 species with significant differences between the Con group and the Tacro group on days 0 and 14. The Tacro group on day 14 contained significantly different genera than the Con group on day 14 (*P < .05, compared with the Con group, 2-way ANOVA, n = 8). (B) Relative abundances, P-values, and confidence intervals of gut microbiota community at the genus level in the fecal samples from the Con group and the Tacro group on day 14. The relative abundance of Allobaculum, Bacteroides, Clostridiales, Ruminococcus, Rikenellaceae, Ruminococcaceae, Oscillospira, and Lactobacillus was significantly altered in the tacrolimustreated specimens (P < .05, 2-sided Welch t-test). (C) Cladographic representation of the significant differences in the taxa between the Con group and the Tacro group was generated by LEfSe to determine the individual taxa that were significantly associated with the Tacro group (green) and the Con group (red) on day 14. (D) A linear discriminant analysis (LDA) was performed to show the relative differences in the abundance of taxa between the Con group and the Tacro group, and significant differences were observed (LDA > 2, P < .05)
groups. However, compared with the Con group, the percentage of The quantitative data are represented as group means. (A) T cell subpopulations in the PBMCs on days 0 and 14. Compared with the control group, the population of Tregs was significantly increased in the FMT group, which was the same as that in the Tacro group. IL-2 expression in the CD4 + , CD8 + , and Tregs was significantly decreased in the FMT group and the Tacro group (*P < .05, compared with the Con group, 2-way ANOVA, n = 8). (B) T cell subpopulations in the gut-associated lymphoid tissue. In the CM, the Teffs and Tregs were similar to those in the PBMCs. In the MLNs, the population of Tregs was significantly increased in the Tacro group and the FMT group, and the IL-2 expression was not different among these groups (*P < .05, 1-way ANOVA, n = 8)
| High-dose tacrolimus-altered microbiome improves the allograft survival rate in an SKT model
To further confirm the immune regulatory function of the high-dose tacrolimus-induced gut microbiome, SKT was performed as an acute rejection model. The TxTacro group was expected to have minimal effect directly on the immune response because of the low dose of tacrolimus, whereas in the TxFMT group, the altered gut microbiota was expected to have a regulatory effect. The TxT+F group has both effects. No significant differences were observed in the gut microbiota taxa on FMT-0 among the 4 groups. At 14 days after FMT, compared with the Con group, the dominant bacteria taxa that were significantly altered were the same in the TxFMT group and in the TxT+F group (P < .05) (Figures 7A and S9 ).
All allograft skin was rejected within 16 days of SKT in the TxSaline, TxTacro, and TxFMT groups. However, the skin survival rate was significantly increased in the TxT+F group ( Figure 7B ). While the first allograft skin loss occurred within 7 days in the other groups, this loss was delayed until 15 days posttransplantation in the TxT+F group.
At the end of the experiment, the skin survival rate in the TxT+F group was still 50% on day 20, significantly greater than in the other 3 groups (P < .01, log rank test).
The morphologic changes are shown in Figure 7C . The isogenic skin healed without necrosis in all groups within 15 days. The allogeneic graft skin began to undergo necrosis in the TxSaline, TxTacro, and
TxFMT groups within the first 10 days and was shed/absorbed within 15 days. However, the allograft skin in the TxT+F group exhibited only mild rejection ( Figure 7B, C) . Histologically, the allograft skin in the TxSaline, TxTacro, and TxFMT groups on day 10 exhibited features of rejection, including increased inflammatory cells and the destruction of hair follicles, surface ulceration, a degraded squamous epithelium, and a vacuolar epidermis ( Figure 7D ). In contrast, the TxT+F group F I G U R E 7 Gut microbiota community and outcomes in each group in a skin transplantation model. (A) Phylogenetic classification of the taxonomy (genus level) in the fecal samples from each group at the beginning of the experiment (FMT-0) and immediately after 14 days of FMT (FMT-14) . The low dose of tacrolimus had a slight effect on the gut microbiota community, while FMT dominated the taxonomy of the gut microbiota in the TxFMT group and the TxT+F group (*P < .05, compared with the TxSaline group; # P < .05, compared with the TxTacro group, 2-way ANOVA, n = 8) (see text for descriptions of the groups). (B) Allograft skin survival after transplantation. The skin survival rate was significantly increased in the TxT+F group at 50% on the 20th day (**P < 0.01, log rank test). (C) General view after skin transplantation among the 4 groups. An overview of the allograft skin pathology at 0, 5, 10, and 15 days after the transplantation in each group. The allogeneic graft skin began to undergo necrosis in the TxSaline, TxTacro, and TxFMT groups within 10 days but showed only mild rejection in the TxT+F group. (D) Hematoxylin and eosin staining of the allograft skin 10 days after transplantation. Representative photographs of 3 individual samples per group. The TxT+F group had a well-organized epidermis with a well-grown squamous epithelium and hair follicles. CD68 staining showed a lower positive rate in the TxT+F group (magnifications of 4×, 10×, and 40×) exhibited less inflammation and a well-organized epidermis with wellgrown squamous epithelium and hair follicles. The allogeneic skin survival time extended to >20 days after low-dose tacrolimus and FMT treatments. In addition, the staining for CD68, which is a marker used to identify macrophages and monocytes and represents inflammatory and nonspecific immune responses in the allograft skin, showed a much lower positive rate in the TxT+F group compared with other 3 groups ( Figure 7D ).
The draining lymph node cells at SKT7 were characterized by flow cytometry. No significant differences were observed in the percentages of CD4 + T cells among the 4 groups ( Figure 8A) . However, the percentages of Tregs in the TxFMT and TxT+F groups were significantly higher than those in the TxSaline and TxTacro groups (P < .05).
Consistent with the serum and colonic results, the IL-2 expression level in the CD4 + cells, CD8 + cells, and Tregs in both the TxFMT group and the TxT+F group was significantly lower than that in the TxSaline group and the TxTacro group (P < .05). Moreover, the trend to a higher fraction of Tregs and lower IL-2 expression was significantly greater in the TxT+F group than in the TxFMT group (P < .05). Regarding proinflammatory cytokines ( Figure 8B ), TNF-α was significantly lower in the TxFMT and TxT+F groups than in the Con and TxTacro groups (P < .05).
IL-17 was significantly lower in the TxT+F group than in the Con and
TxFMT groups. IFNγ was significantly higher in the TxFMT group than in the Con and TxTacro groups (P < 0.05).
| DISCUSSION
In this study, we demonstrated that high-dose tacrolimus affects the gut microbiota, having an important functional impact. The transfer of feces harvested from high-dose tacrolimus-treated mice and administered to recipients along with low-dose tacrolimus significantly suppressed recipient systemic immune function and extended the allograft survival rate in an SKT model. Based on the α-diversity, we observed that the bacterial richness and diversity in the fecal samples did not change after tacrolimus administration. However, the β-diversity analysis revealed that the tacrolimus-treated mice had a fecal microbial composition that differed from that in the Con group. Consistent with a previous study, no significant difference was observed at the phylum level in the fecal microbiota between the tacrolimus-treated mice and the Con mice. However, 9 families (Erysipelotrichaceae, Dehalobacteriaceae, Bacteroidaceae, Rikenellaceae, Odoribacteraceae, Planococcaceae, Christensenellaceae, Eubacteriaceae, and F16) were significantly changed, and the first 3 families were consistent with a previous study. 17 At the genera level, inflammatory bowel diseases, irritable bowel syndrome, diabetes, obesity, and dysbiosis-related diseases. 25 These changes support the protective and regulative functions of tacrolimus on the gut microbiota. [26] [27] [28] However, this was a prediction, and the specific changes observed might not directly influence the host's metabolic capacity; thus, further studies are needed to shed more light on this topic.
According to our results, only the high-dose tacrolimus treatment group exhibited significant changes in the gut microbiota, supporting that tacrolimus exerts a dosage-dependent effect on the gut microbi- 
